Quality by Design (QbD) Based Development and Optimization of Levocetirizine Sustained Release Oral Tablets

1.1 Allergic Disorders and Their Global Burden

Allergic disorders are among the most common chronic conditions worldwide, affecting individuals across all age groups. Rapid urbanization, environmental pollution, changing lifestyles, and genetic predisposition have contributed to the rising prevalence of allergic diseases. These disorders not only reduce quality of life but also impose a considerable economic burden due to healthcare costs and loss of productivity.^[1]

Allergic rhinitis is a chronic inflammatory condition of the nasal mucosa triggered by exposure to allergens such as pollen, dust mites, animal dander, or mold. It is clinically characterized by sneezing, nasal congestion, rhinorrhea, itching, and watery eyes. Although not life-threatening, persistent symptoms can interfere with sleep, concentration, work efficiency, and daily activities. In many patients, allergic rhinitis is associated with other atopic conditions such as asthma, further complicating disease management. ^[2]

Chronic urticaria is another common allergic disorder marked by recurrent wheals (hives), itching, and sometimes angioedema lasting for more than six weeks. The condition may significantly affect psychological well-being due to visible skin lesions and persistent discomfort. Management often requires long-term antihistamine therapy to control symptoms and prevent recurrence. ^[3]

Figure no 1. Allergic Disorders and types

1.2 Levocetirizine

Levocetirizine is a third-generation, non-sedating antihistamine widely prescribed for the treatment of allergic rhinitis and chronic urticaria. Chemically, it is the active enantiomer of cetirizine and belongs to the piperazine derivative class of antihistamines. ^[4]Its selective activity contributes to improved efficacy and reduced central nervous system side effects compared to earlier antihistamines. ^[5] The primary mechanism of action of levocetirizine involves selective antagonism of peripheral histamine H1 receptors. By blocking these receptors, it prevents histamine-mediated allergic responses such as vasodilation, increased vascular permeability, itching, and mucosal edema. As a result, it effectively alleviates symptoms associated with allergic conditions. ^[6]

Pharmacokinetically, levocetirizine is rapidly absorbed after oral administration, with high bioavailability and minimal hepatic metabolism. It is primarily excreted unchanged through the kidneys. ^[7] Despite these advantages, the drug has a relatively moderate elimination half-life, which may necessitate regular dosing to maintain therapeutic plasma levels. Although generally well tolerated, mild adverse effects such as drowsiness, dry mouth, and fatigue may occur in some patients. ^[8]

1.3 Need for Sustained Release Formulation

Conventional immediate-release formulations of levocetirizine are effective but may present certain limitations in long-term therapy. One of the primary concerns is the need for repeated dosing to maintain consistent therapeutic levels in the bloodstream. Even with once-daily dosing, plasma drug concentration may fluctuate, leading to variations in symptom control. ^[9]

Fluctuations in plasma levels can result in periods of sub-therapeutic exposure or higher peak concentrations, potentially affecting efficacy and tolerability. For chronic conditions such as allergic rhinitis and urticaria, maintaining stable drug concentrations is crucial for sustained symptom relief. Sustained release (SR) formulations offer a promising solution to these challenges. By controlling the rate of drug release over an extended period, SR systems help maintain steady plasma concentrations, reduce dosing frequency, and enhance patient adherence. Improved compliance is particularly important in chronic allergic disorders where long-term treatment is required. Therefore, the development of a sustained release formulation of levocetirizine represents a rational and clinically relevant approach to optimizing therapy and improving patient outcomes. ^[10]

2. Levocetirizine: Drug Profile

2.1 Chemical Structure

Figure no. 2 Levocetirizine structure

Levocetirizine is the pharmacologically active R-enantiomer of cetirizine and belongs to the piperazine derivative class of antihistamines. Chemically, it is designated as (R)-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride. The presence of a piperazine ring, aromatic rings, and a carboxylic acid functional group plays a crucial role in its antihistaminic activity and physicochemical behavior. ^[11]

The molecular formula of levocetirizine dihydrochloride is C??H??ClN?O?·2HCl, and it has a molecular weight of approximately 461.8 g/mol (dihydrochloride salt). The molecule exhibits chirality, and the R-enantiomer demonstrates higher affinity and selectivity toward peripheral H1 receptors compared to the S-enantiomer. This stereochemical specificity contributes to its enhanced therapeutic profile and reduced adverse effects.

2.2 Physicochemical Properties

Understanding the physicochemical characteristics of levocetirizine is essential for designing an effective sustained release formulation.

• pKa: Levocetirizine possesses both acidic and basic functional groups. The carboxylic acid group exhibits a pKa in the acidic range, while the piperazine nitrogen contributes to basicity. This amphoteric nature influences its ionization behavior across gastrointestinal pH conditions.
• Solubility: Levocetirizine dihydrochloride is freely soluble in water and polar solvents. Its good aqueous solubility supports rapid dissolution in conventional formulations but may require appropriate matrix-forming polymers in sustained release systems to control drug release.
• LogP (Partition Coefficient): Levocetirizine exhibits moderate lipophilicity, reflected by a relatively low to moderate logP value. This balance between hydrophilicity and lipophilicity favors adequate membrane permeability while maintaining good solubility. ^[12]

2.3 Biopharmaceutical Classification System (BCS) Classification

According to the Biopharmaceutical Classification System (BCS), levocetirizine is generally categorized under BCS Class III (high solubility and low permeability). Drugs in this class dissolve readily in gastrointestinal fluids but may have limited membrane permeability.

For sustained release formulation development, BCS Class III drugs require careful consideration of factors affecting gastrointestinal transit time and absorption window. Since levocetirizine is highly soluble, controlling its release rate through polymeric matrices becomes essential to prevent rapid drug diffusion and ensure prolonged therapeutic action.

2.4 Pharmacokinetics ^[13]

Absorption

Levocetirizine is rapidly and extensively absorbed following oral administration. It demonstrates high oral bioavailability, indicating minimal first-pass metabolism. Peak plasma concentrations are typically achieved within a short period after dosing.

Distribution

The drug exhibits moderate plasma protein binding and distributes primarily within extracellular fluids. Due to its relatively low penetration across the blood–brain barrier, central nervous system side effects such as sedation are minimal compared to first-generation antihistamines.

Metabolism

Levocetirizine undergoes minimal hepatic metabolism. A small fraction of the administered dose is metabolized via oxidation and conjugation pathways, which reduces the risk of significant drug–drug interactions.

Elimination

The drug is predominantly excreted unchanged through renal pathways. Its elimination half-life supports once-daily dosing; however, plasma concentration may gradually decline, which justifies exploring sustained release formulations for prolonged therapeutic coverage.

2.5 Stability Considerations ^[14]

Stability plays a critical role in formulation development and shelf-life determination. Levocetirizine dihydrochloride is generally stable under normal storage conditions but may be sensitive to:

• Moisture: Hygroscopicity may affect tablet integrity and dissolution characteristics.
• Heat: Elevated temperatures can accelerate degradation.
• Light exposure: Protection from direct light may be necessary during storage.

In sustained release matrix formulations, compatibility with polymers and excipients must be evaluated through preformulation studies such as FT-IR, DSC, and accelerated stability testing. Understanding degradation pathways and environmental sensitivities ensures the development of a stable and robust dosage form.

Table 1: Drug Profile of Levocetirizine

3. Sustained Release Oral Drug Delivery Systems

3.1 Concept and Principles

Sustained release (SR) oral drug delivery systems are designed to release a drug at a predetermined rate for an extended period of time in order to maintain therapeutic drug levels in the bloodstream. The primary objective of sustained release formulations is to reduce dosing frequency, improve patient adherence, and minimize fluctuations in plasma drug concentration. ^[11]

Although the terms controlled release and sustained release are often used interchangeably, there is a subtle distinction between them. Sustained release systems prolong drug release over time but may not maintain a constant release rate. In contrast, controlled release systems are specifically designed to deliver the drug at a nearly constant rate, ideally following zero-order kinetics. Controlled release is therefore considered a more precise and advanced form of sustained release. ^[15]

Table 2: Comparison – Conventional vs Sustained Release Tablets

Mechanisms of Drug Release ^[16]

Drug release from sustained release tablets can occur through one or more of the following mechanisms:

1. Diffusion-Controlled Release
   The drug diffuses from the dosage form into the surrounding dissolution medium through pores or polymeric networks. The rate of diffusion depends on drug solubility, polymer characteristics, and matrix porosity.
2. Erosion-Controlled Release
   In this mechanism, the polymer matrix gradually erodes or dissolves in the gastrointestinal fluids, releasing the embedded drug over time.
3. Osmotic Pressure-Controlled Release
   Water enters the dosage form due to osmotic pressure differences, generating internal pressure that pushes the drug solution out through a delivery orifice at a controlled rate.
4. Swelling-Controlled Release
   Hydrophilic polymers absorb water and swell, forming a gel barrier around the tablet. The drug then diffuses slowly through this hydrated gel layer.

In practice, many sustained release systems operate through a combination of these mechanisms.

Figure no. 3 Mechanisms of Drug Release

3.2 Types of Sustained Release Systems

1. Matrix Systems ^[17]

Matrix systems are among the most widely used sustained release formulations due to their simplicity and cost-effectiveness. In these systems, the drug is uniformly dispersed within a polymer matrix.

• Hydrophilic Matrix Systems:
  These systems use water-swellable polymers such as HPMC. Upon contact with gastrointestinal fluids, the polymer hydrates and forms a gel layer that controls drug diffusion.
• Hydrophobic Matrix Systems:
  These systems use water-insoluble polymers such as ethyl cellulose or waxes. Drug release occurs primarily through diffusion via pores and channels formed within the matrix.

Matrix systems are particularly suitable for highly soluble drugs, as polymer concentration can be adjusted to modulate release rate.

2. Reservoir Systems

In reservoir systems, the drug core is surrounded by a polymeric membrane that controls drug release. The membrane acts as a barrier regulating diffusion of the drug into the external environment. While reservoir systems can provide more precise release control, they require more complex manufacturing processes.

3. Osmotic Pump Systems ^[18]

Osmotic systems utilize osmotic pressure as the driving force for drug release. These tablets contain an osmotic agent and are coated with a semipermeable membrane having a small delivery orifice. Water influx generates pressure, which pushes the drug solution out at a controlled rate. Osmotic systems are capable of achieving near zero-order release kinetics.

4.3 Polymers Used in Sustained Release Tablets ^[19]

Polymers play a crucial role in determining the release behavior and performance of SR tablets.

Hydroxypropyl Methylcellulose (HPMC)

HPMC is one of the most commonly used hydrophilic matrix-forming polymers. Different viscosity grades such as K4M, K15M, and K100M are selected depending on the desired release rate. Higher viscosity grades provide stronger gel formation and slower drug release.

Ethyl Cellulose

Ethyl cellulose is a hydrophobic polymer widely used in matrix and coating systems. It controls drug release primarily through diffusion and is particularly useful for highly water-soluble drugs.

Carbopol

Carbopol is a cross-linked polyacrylic acid polymer known for its high swelling capacity. It forms a viscous gel upon hydration and can effectively retard drug release.

Natural Polymers ^[20]

Natural polymers such as guar gum, xanthan gum, chitosan, and alginate are increasingly explored due to their biodegradability, biocompatibility, and cost-effectiveness. They can provide controlled release through swelling and gel formation mechanisms.

Table 6: Polymers Used in SR Tablets

3.4 Advantages and Limitations of Sustained Release Tablets ^[21]

Advantages

• Reduced dosing frequency
• Improved patient compliance
• Maintenance of steady plasma drug levels
• Reduced peak–trough fluctuations
• Potential reduction in side effects
• Improved therapeutic efficacy in chronic conditions

Limitations

• Risk of dose dumping in case of formulation failure
• Not suitable for drugs with very short half-life or narrow absorption window
• Higher manufacturing complexity and cost
• Limited flexibility in dose adjustment
• Possible variability due to gastrointestinal transit conditions

In summary, sustained release oral drug delivery systems provide significant therapeutic and patient-centered benefits, particularly for chronic conditions requiring long-term medication. However, careful formulation design and optimization are essential to ensure safety, efficacy, and consistent performance.

4. Quality by Design (QbD) in Pharmaceutical Development

4.1 Concept of Quality by Design (QbD)

Quality by Design (QbD) is a systematic, science-based, and risk-oriented approach to pharmaceutical product development. It emphasizes building quality into the product from the initial stages of formulation and process design rather than relying solely on end-product testing. According to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, QbD is defined as “a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management.” ^[22]

Comparison with the Traditional Approach

In the traditional pharmaceutical development approach, product quality is often evaluated primarily through finished product testing. This method relies heavily on trial-and-error experimentation and fixed process parameters. If the final product fails to meet specifications, reformulation or process adjustments are required. ^[23] In contrast, QbD focuses on understanding the relationship between formulation variables, process parameters, and product performance. It integrates risk assessment, statistical tools, and process control strategies to ensure consistent quality. Rather than testing quality into the product, QbD builds quality into the product during development.

4.2 ICH Guidelines Related to QbD ^[24]

Several guidelines developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use provide the regulatory framework for implementing QbD in pharmaceutical development:

• ICH Q8 (Pharmaceutical Development):
  Introduces the concept of QbD and emphasizes the importance of understanding formulation and process variables. It highlights the development of Quality Target Product Profile (QTPP) and establishment of design space.
• ICH Q9 (Quality Risk Management):
  Provides guidance on systematic risk assessment methodologies such as Failure Mode and Effects Analysis (FMEA) and other risk management tools.
• ICH Q10 (Pharmaceutical Quality System):
  Describes a comprehensive quality management system covering product lifecycle management.
• ICH Q11:
  Focuses on development and manufacture of drug substances, aligning with QbD principles.

Together, these guidelines form the foundation for modern, regulatory-compliant pharmaceutical development.

4.3 Key Elements of QbD^[25]

Quality Target Product Profile (QTPP)

QTPP defines the intended characteristics of the final product, including dosage form, route of administration, strength, release profile, stability, and safety attributes.

Critical Quality Attributes (CQAs)

CQAs are physical, chemical, biological, or microbiological properties that must be controlled within specific limits to ensure product quality.

Critical Material Attributes (CMAs)

CMAs refer to the properties of raw materials (e.g., particle size, polymer viscosity, moisture content) that can impact product quality.

Critical Process Parameters (CPPs)

CPPs are process variables such as mixing time, compression force, and granulation temperature that significantly influence CQAs.

Risk Assessment Tools

Common tools include:

• Failure Mode and Effects Analysis (FMEA)
• Ishikawa (Fishbone) diagram
  These tools help identify high-risk variables affecting product quality.

Control Strategy

A planned set of controls derived from process understanding that ensures consistent product quality throughout manufacturing. ^[26]

Design Space

Design space is the multidimensional combination of CMAs and CPPs that has been demonstrated to assure quality. Operating within this space ensures regulatory flexibility and consistent performance.

Table 3: Key Elements of QbD